WLWenzhi Li

Wenzhi Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wenzhi Li has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Shutian Jiang

    Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    7 shared publications
  • Qifeng Lyu

    Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

    5 shared publications
  • Yanping Kuang

    Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine

    5 shared publications
  • Xueyi Jiang

    Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

    4 shared publications
  • Li Chen

    Department of Assisted Reproduction, Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

    3 shared publications
  • Xinxi Zhao

    Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

    3 shared publications

Latest Publications

  • Open Access

    The value of the pronucleus size of human single pronucleus zygotes as a predictor of fertility outcomes in conventional in vitro fertilization: a retrospective cohort study

    by Yan Mi, Danjun Li, Xueyi Jiang, Wenzhi Li, Shutian Jiang, Qifeng Lyu

    Embryos derived from in vitro fertilization (IVF) single pronucleus (1PN) zygotes can achieve live births. The pronucleus size of 1PN zygotes is related to

  • Open Access

    NAD+-dependent Sirt6 is a key regulator involved in telomere shortening of in vitro-cultured preimplantation embryos

    by Danjun Li, Wenzhi Li, Xiaoyu Liao, Shutian Jiang, Meng Ma, Zhijie Hu, Kaibo Lin, Weina Yu, Xue Sun, Yong Fan, et al.

    Telomere length (TL) is important for maintaining the individual health of a species. Recent studies shows that in vitro fertilization therapy can drastically reduce TL in offspring, however, the underlying molecular mechanism remains unknown. Sirt6 is a NAD+-dependent epigenetic regulator that has recently been found to play an important role in maintaining telomere stability. Here, we report that NAD+ deficiency in in vitro-cultured blastocysts impairs Sirt6 function, triggering telomere shortening of the inner cell mass and possibly affecting newborns. This phenotype could be effectively mitigated by supplementation with nicotinamide mononucleotide (NAD+ precursor) during in vitro culture, while it could not be achieved in Sirt6 conditional knockout embryos. mtROS accumulation and epigenetic modifications may also be involved in this process. Our results reveal the mechanism by which in vitro culture induces telomere shortening in preimplantation embryos, providing a potential target for improving in vitro culture conditions.


  • Open Access

    The impact of unexplained spontaneous miscarriage history on cycle outcomes in patients undergoing in vitro fertilization: an analysis of 6535 patients

    by Shutian Jiang, Xueyi Jiang, Yanping Kuang, Wenzhi Li

    To investigate whether the previous spontaneous miscarriages affect the cycle outcomes in in vitro fertilization and embryo transfer (IVF-ET). Comparisons were made on the cycle characteristics and outcomes between patients (underwent their first IVF-ET cycles between January 2018 and June 2022) without (Group A) and with (Group B) spontaneous miscarriage histories. Multiple regression analysis was performed to adjust for other possible confounders of cycle outcomes. In controlled ovarian stimulation cycles, the rate of viable embryos per oocyte in group A was higher than that in group B (0.40 ± 0.26 vs. 0.38 ± 0.27, p = 0.006). Multiple linear regression analysis confirmed that the previous miscarriage history was negatively associated with the oocyte utilization rate (p = 0.002). Moreover, in ET cycles, no statistical difference was observed regarding the miscarriage rate between the two groups (p = 0.497), while Group B presented with lower clinical pregnancy rate (46.1% vs. 42.3%, p = 0.006), lower ongoing pregnancy rate (40.5% vs. 37.0%, p = 0.009) and lower live birth rate (38.5% vs. 35.0%, p = 0.009). Further binary logistic regression analysis demonstrated that the previous miscarriage history had no significant effect on these pregnancy outcomes. For patients receiving IVF-ET treatment, a miscarriage history is related to a lower oocyte utilization rate. However, there was no association between previous history of miscarriage and the pregnancy outcomes (e.g. miscarriage rate, pregnancy rate, live birth rate), once the patients had acceptable embryos for later transfer.


  • Open Access

    Laser-assisted hatching is associated with reduced re-expansion of vitrified-thawed blastocysts and has no significant effect on embryo implantation

    by Shutian Jiang, Xueyi Jiang, Yan Mi, Xue Sun, Qifeng Lyu, Wenzhi Li

    Studies have shown that vitrified-thawed blastocyst re-expansion capacity is a good predictor of implantation. However, whether assisted hatching (AH) influences re-expansion is currently unstudied. Also, whether AH improves subsequent implantation rate remains highly uncertain. To investigate the impact of AH on re-expansion and subsequent implantation in vitrified-thawed blastocysts transfer cycles. The absolute initial single vitrified-thawed blastocyst cycles of patients between August 2019 and April 2024 in our center were included in this retrospective cohort study, totaling 4637 cycles. Grouping was performed according to laser-AH or not. Stratified analyses according to different trophoblastic ectoderm (TE) grades were applied (TE were categorized into three different grades (A-C) according to their number and cohesiveness), with specific focus on blastocysts with TE grade of C. Subgroup analyses were then carried out based on blastocyst stage (Day5 or Day6), in which AH and Non-AH were compared separately. Multifactorial regression analyses were performed on the main outcomes to clarify the effect of laser-AH. There were no differences in pregnancy outcomes between AH group and Non-AH group, though the blastocyst stage proportions differed. Subgroup analysis based on blastocyst stage still revealed no statistically significant differences in pregnancy outcomes regarding AH or not (both in Day5 and Day6 blastocysts); while AH group had a lower re-expansion rate than Non-AH group in Day6 blastocysts (78.9% vs. 84.0%, P = 0.006). Multifactorial regression showed that AH had no effect on biochemical pregnancy rate in all cycles (aOR: 1.064, 95% CI: 0.938–1.206, P = 0.337), but increased the probability of implantation in TE grade = C cycles (aOR: 1.340, 95% CI: 1.017–1.766, P = 0.038). In the binary regression analysis on re-expansion rate, AH presented a negative effect both in all cycles and in TE grade = C cycles (all cycles: aOR: 0.774, 95% CI: 0.646–0.827, P = 0.005; TE = C cycles: aOR: 0.688, 95% CI: 0.481–0.984, P = 0.040). Laser-AH negatively affects the ability of vitrified-thawed blastocysts to re-expand. Laser-AH had no significant effect on implantation in all blastocysts. AH may only be beneficial for the implantation of blastocysts with TE grade C. Not applicable.


  • Open Access

    Earlier second polar body transfer and further mitochondrial carryover removal for potential mitochondrial replacement therapy

    by Wenzhi Li, Xiaoyu Liao, Kaibo Lin, Renfei Cai, Haiyan Guo, Meng Ma, Yao Wang, Yating Xie, Shaozhen Zhang, Zhiguang Yan, et al.

    The second polar body (PB2) transfer in assisted reproductive technology is regarded as the most promising mitochondrial replacement scheme for preventing the mitochondrial disease inheritance owing to its less mitochondrial carryover and stronger operability. However, the mitochondrial carryover was still detectable in the reconstructed oocyte in conventional second polar body transfer scheme. Moreover, the delayed operating time would increase the second polar body DNA damage. In this study, we established a spindle‐protrusion‐retained second polar body separation technique, which allowed us to perform earlier second polar body transfer to avoid DNA damage accumulation. We could also locate the fusion site after the transfer through the spindle protrusion. Then, we further eliminated the mitochondrial carryover in the reconstructed oocytes through a physically based residue removal method. The results showed that our scheme could produce a nearly normal proportion of normal‐karyotype blastocysts with further reduced mitochondrial carryover, both in mice and humans. Additionally, we also obtained mouse embryonic stem cells and healthy live‐born mice with almost undetectable mitochondrial carryover. These findings indicate that our improvement in the second polar body transfer is conducive to the development and further mitochondria carryover elimination of reconstructed embryos, which provides a valuable choice for future clinical applications of mitochondrial replacement.


  • Open Access

    The impact of blastomere loss on pregnancy and neonatal outcomes of vitrified-warmed Day3 embryos in single embryo transfer cycles

    by Shutian Jiang, Wei Jin, Xinxi Zhao, Qianwen Xi, Li Chen, Yining Gao, Wenzhi Li, Yanping Kuang

    Background: Blastomere loss is a common phenomenon that occurs following cryopreservation. To date, studies have drawn conflicting conclusions regarding the impact of blastomere loss on pregnancy outcomes. Besides, limited information is available concerning the neonatal safety of embryos with blastomere loss. In the present study, we aimed to investigate the impact of blastomere loss on pregnancy and neonatal outcomes of vitrified/warmed Day3 cleavage-stage embryos in single embryo transfer cycles. Methods: This retrospective cohort study included all vitrified/warmed D3 cleavage-stage single frozen-thawed embryo transfer (FET) cycles between April 2015 and February 2021. We compared pregnancy and subsequent neonatal outcomes between the intact embryos group and the blastomere loss group in single FET cycles. Results: A total of 6287 single FET cycles were included in the study, in which 5873 cycles were classified into the intact embryo group and 414 cycles were classified into the blastomere loss group. The outcomes of the blastomere loss group were significantly inferior to those of the intact embryo group, in terms of implantation/biochemical pregnancy/clinical pregnancy/ongoing pregnancy rate and live birth rate per embryo transfer cycle/per clinical pregnancy. Further binary logistic regression confirmed that blastomere loss was negatively associated with live birth. Moreover, the blastomere loss group presented with an elevated early miscarriage rate. The neonatal conditions were broadly similar between the two groups. Additionally, multiple binary logistic regression analysis demonstrated that primary infertility and intracytoplasmic sperm injection (ICSI) were common influencing factors of blastomere loss (aOR 1.447, 95% CI 1.038–2.019, P = 0.029; aOR: 1.388, 95% CI: 1.044–51.846, P = 0.024). Conclusions: The transfer of vitrified/warmed D3 embryos with blastomere loss is related to impaired embryo developmental potentials and reduced probabilities of conception. Moreover, even if the embryos with blastomere loss have implanted and reached clinical pregnancies, they present with a lower possibility of developing to live birth owing to a higher early miscarriage rate. However, once the embryos with blastomere loss result in a live birth, no adverse neonatal outcomes are observed. Primary infertility and ICSI were found to be risk factors for blastomere loss.


  • Open Access

    The Effect of Spontaneous LH Surges on Pregnancy Outcomes in Patients Undergoing Letrozole-HMG IUI: A Retrospective Analysis of 6,285 Cycles

    by Shutian Jiang, Li Chen, Yining Gao, Qianwen Xi, Wenzhi Li, Xinxi Zhao, Yanping Kuang

    Background: To date, no consensus has been reached on whether to wait for spontaneous luteinizing hormone (LH) surge to occur or to trigger ovulation regardless of the presence of an LH surge for achieving higher success rate in intrauterine insemination (IUI) cycles. Therefore, we hope to investigate the effect of the presence of a spontaneous LH surge on pregnancy outcomes in letrozole–human menopausal gonadotropin (LE-HMG) IUI cycles.Methods: In this retrospective cohort study, a total of 6,285 LE-HMG IUI cycles were included between January 2010 and May 2021. Cycles were categorized into three groups: the trigger + LH surge group, the trigger only group, and the LH surge only group. The primary outcome measure was the clinical pregnancy rate. A logistic regression analysis was performed to explore other risk factors affecting the clinical pregnancy rate.Results: No significant differences were observed in biochemical pregnancy rate (P =0.640), clinical pregnancy rate (P =0.702), ongoing pregnancy rate (P =0.842), and live birth rate (P =0.951) among the three groups. The binary logistic regression analysis also confirmed that the existence of an LH surge was not associated with clinical pregnancy. There was a difference in ectopic pregnancy rates (P =0.045), but logistic regression showed that the presence of a spontaneous LH surge has no association with ectopic pregnancy. Nonetheless, patients with lead follicles within 18.1-20.0 mm/20.1-22.0 mm and a long duration of LE treatment were less likely to get ectopic pregnant compared with patients with 14.1-16.0 mm lead follicles and shorter LE treatment (OR: 0.142, 95% CI: 0.023–0.891, P =0.037; OR: 0.142, 95% CI: 0.022–0.903, P =0.039; OR: 0.445, 95% CI: 0.235–0.840, P = 0.013).Conclusions: The presence of a spontaneous LH surge in triggered LE-HMG IUI cycles does not appear to improve pregnancy rates. Thus, we suggest that waiting for an LH surge to occur is not necessary in triggered LE-HMG IUI cycles.


  • Open Access

    Nintedanib Treatment After Ovulation is an Effective Therapeutic Strategy for the Alleviation of Ovarian Hyperstimulation Syndrome (OHSS) in a Mouse Model

    by Shutian Jiang, Wenzhi Li, Xinxi Zhao, Li Chen, Yanping Kuang

    Purpose: Ovarian hyperstimulation syndrome (OHSS) is a serious complication of controlled ovarian hyperstimulation. In this study, we hope to explore whether nintedanib, a tyrosine kinase inhibitor, can inhibit OHSS by blocking signaling of vascular endothelial growth factor in a mouse model. Considering that nintedanib been approved for the treatment of some diseases. We believe that nintedanib has important potential in the treatment of OHSS. Methods: Female ICR mice aged 6– 8 weeks with similar initial weights were used to establish the OHSS model. At 12 and 24 hours after human chorionic gonadotropin (hCG) trigger, we administered nintedanib by subcutaneous injection and analyzed the OHSS-related physiological characteristics and biochemical indices of the model mice within 48 hours after hCG-trigger. Results: Nintedanib significantly alleviated the symptoms of OHSS after hCG-trigger compared with those of OHSS group (weight change, P < 0.0001; ovarian weight, P < 0.0001, peritoneal exudation level, P < 0.01). Further investigation proved that the corpus luteum (number, P < 0.001; diameter, P < 0.0001) and luteal vessel (P < 0.0001) development were inhibited in the nintedanib administration group. Then, the vascular permeability test showed that the capillary bleeding points (P < 0.0001) were also significantly reduced in nintedanib administration group. Gene expression tests demonstrated that the intercellular connection-related genes expression in the nintedanib administration group was similar to that in the no-OHSS induced group. Further detection of coagulation and thrombosis indices indicated that the nintedanib administration in the OHSS model did not increase the risk of thrombosis or bleeding. Conclusion: Our study demonstrated that nintedanib can alleviate and manage the symptoms of OHSS in a mouse model. These findings identify a feasible scheme for the prevention and treatment of OHSS in clinical practice in the future. Moreover, since the scheme can be implemented after ovulation, it will not cause potential adverse effects on gametogenesis, fertilization or embryonic development.